Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 1
2005 3
2006 2
2007 2
2009 1
2010 2
2011 3
2013 2
2014 1
2015 2
2016 1
2017 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
DT56a (Femarelle): a natural selective estrogen receptor modulator (SERM).
Somjen D, Katzburg S, Knoll E, Hendel D, Stern N, Kaye AM, Yoles I. Somjen D, et al. J Steroid Biochem Mol Biol. 2007 May;104(3-5):252-8. doi: 10.1016/j.jsbmb.2007.03.004. Epub 2007 Mar 14. J Steroid Biochem Mol Biol. 2007. PMID: 17428655
A selective estrogen receptor modulator (SERM) is defined as a substance with dissimilar effects on different tissues: agonist in some and antagonists in others. The natural compound DT56a (Femarelle) was shown to activate estrogen receptors in human cultured female …
A selective estrogen receptor modulator (SERM) is defined as a substance with dissimilar effects on different tissues: agonist in some and a …
Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial.
Chen FP, Chang CJ, Chao AS, Huang HY, Huang JP, Wu MH, Tsai CC, Kung FT, Chang CW, Tsai YC. Chen FP, et al. Taiwan J Obstet Gynecol. 2016 Jun;55(3):336-40. doi: 10.1016/j.tjog.2016.04.008. Taiwan J Obstet Gynecol. 2016. PMID: 27343311 Free article. Clinical Trial.
OBJECTIVE: To assess the effects of 2 months of treatment with Femarelle for climacteric syndrome in Taiwanese postmenopausal women. ...After 4 weeks and 8 weeks of treatment with Femarelle, patients showed statistically significant improvement in climacteric sympto …
OBJECTIVE: To assess the effects of 2 months of treatment with Femarelle for climacteric syndrome in Taiwanese postmenopausal women. …
DT56a (Femarelle), contrary to estradiol-17beta, is effective in human derived female osteoblasts in hyperglycemic condition.
Somjen D, Katzburg S, Sharon O, Hendel D, Yoles I. Somjen D, et al. J Steroid Biochem Mol Biol. 2011 Jan;123(1-2):25-9. doi: 10.1016/j.jsbmb.2010.10.001. Epub 2010 Oct 14. J Steroid Biochem Mol Biol. 2011. PMID: 20951203
We have reported previously, that female-derived cultured osteoblasts (hObs) responded to DT56a (Femarelle) measured by the stimulation of creatine kinase specific activity (CK), which is a marker for hormone responsiveness and (3)[H] thymidine incorporation into DN …
We have reported previously, that female-derived cultured osteoblasts (hObs) responded to DT56a (Femarelle) measured by the st …
Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss.
Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B. Yoles I, et al. Menopause. 2003 Nov-Dec;10(6):522-5. doi: 10.1097/01.GME.0000064864.58809.77. Menopause. 2003. PMID: 14627860 Clinical Trial.
OBJECTIVE: To evaluate the efficacy of Tofupill/Femarelle (DT56a), a novel phyto-selective estrogen receptor modulator (SERM), in preserving bone mineral density (BMD) in postmenopausal women. DESIGN: The study sample consisted of 98 healthy, postmenopausal women wh …
OBJECTIVE: To evaluate the efficacy of Tofupill/Femarelle (DT56a), a novel phyto-selective estrogen receptor modulator (SERM), …
DT56a (Femarelle) stimulates bone formation in female rats.
Somjen D, Katzburg S, Livne E, Yoles I. Somjen D, et al. BJOG. 2005 Jul;112(7):981-5. doi: 10.1111/j.1471-0528.2005.00573.x. BJOG. 2005. PMID: 15958004
OBJECTIVE: DT56a is a natural compound for the treatment of menopausal symptoms and osteoporosis. ...CONCLUSIONS: DT56a was as effective as oestrogen in reversing the bone changes caused by OVX in rats....
OBJECTIVE: DT56a is a natural compound for the treatment of menopausal symptoms and osteoporosis. ...CONCLUSIONS: DT56a was as …
A prospective study of DT56a (Femarelle) for the treatment of menopause symptoms.
Sánchez-Borrego R, Mendoza N, Llaneza P. Sánchez-Borrego R, et al. Climacteric. 2015;18(6):813-6. doi: 10.3109/13697137.2015.1065247. Epub 2015 Oct 10. Climacteric. 2015. PMID: 26455645
BACKGROUND: DT56a (Femarelle) is a natural medication that contains a variety of phytoestrogens derived from tofu. Treatment with DT56a affects bones, vascular tissues and the nervous system in a manner similar to that of estrogen but DT56a acts as an …
BACKGROUND: DT56a (Femarelle) is a natural medication that contains a variety of phytoestrogens derived from tofu. Treatment w …
The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women.
Nachtigall MJ, Jessel RH, Flaumenhaft R, Nachtigall R, Yoles I, Naftolin F, Nachtigall LE. Nachtigall MJ, et al. Menopause. 2011 Mar;18(3):285-8. doi: 10.1097/gme.0b013e3181f2f01a. Menopause. 2011. PMID: 21037489
OBJECTIVE: The purpose of this study was to assess the effect of DT56a (Femarelle), a selective estrogen receptor modulator, on platelet function in normal and thrombophilic women being treated for severe menopausal symptoms. ...The regression curve for measures ove …
OBJECTIVE: The purpose of this study was to assess the effect of DT56a (Femarelle), a selective estrogen receptor modulator, o …
Brain-region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats.
Pluchino N, Merlini S, Cubeddu A, Giannini A, Bucci F, Casarosa E, Cela V, Angioni S, Luisi M, Genazzani AR. Pluchino N, et al. Menopause. 2009 Sep-Oct;16(5):1037-43. doi: 10.1097/gme.0b013e31819b351e. Menopause. 2009. PMID: 19295450
OBJECTIVE: The natural selective estrogen receptor modulator DT56a (Femarelle), derived from soybean, has been shown to relieve menopausal vasomotor symptoms with no effect on sex steroid hormone levels or endometrial thickness.The purpose of the present study was t …
OBJECTIVE: The natural selective estrogen receptor modulator DT56a (Femarelle), derived from soybean, has been shown to reliev …
Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms.
Yoles I, Yogev Y, Frenkel Y, Hirsch M, Nahum R, Kaplan B. Yoles I, et al. Clin Exp Obstet Gynecol. 2004;31(2):123-6. Clin Exp Obstet Gynecol. 2004. PMID: 15266766 Clinical Trial.
OBJECTIVE: In a previous study treatment with a daily standard dose of Femarelle (644 mg/day) resulted in a significant elevation in bone mineral density (BMD) while a reduced dose resulted in a decrease in BMD. The aim of the current study was to examine the efficacy and …
OBJECTIVE: In a previous study treatment with a daily standard dose of Femarelle (644 mg/day) resulted in a significant elevation in …
Interaction between the effects of the selective estrogen modulator femarelle and a vitamin D analog in human umbilical artery vascular smooth muscle cells.
Somjen D, Knoll E, Sharon O, Many A, Stern N. Somjen D, et al. J Steroid Biochem Mol Biol. 2017 Nov;174:9-13. doi: 10.1016/j.jsbmb.2017.05.007. Epub 2017 May 20. J Steroid Biochem Mol Biol. 2017. PMID: 28536085
To further investigate the interaction between vitamin D system and estrogen-mimetic compounds in the human vasculature we studied the effect of the "less- calcemic" analog of 1,25(OH)(2)D(3) (1,25D); JK 1624F(2)-2 (JKF) in the presence of selective estrogen modulator femarell …
To further investigate the interaction between vitamin D system and estrogen-mimetic compounds in the human vasculature we studied the effec …
21 results